Ruth Link-Gelles
#183,405
Most Influential Person Now
American epidemiologist
Ruth Link-Gelles's AcademicInfluence.com Rankings
Ruth Link-Gellesmedical Degrees
Medical
#3805
World Rank
#4320
Historical Rank
Epidemiology
#836
World Rank
#871
Historical Rank
Download Badge
Medical
Ruth Link-Gelles's Degrees
- PhD Epidemiology Johns Hopkins University
Why Is Ruth Link-Gelles Influential?
(Suggest an Edit or Addition)According to Wikipedia, Ruth Link-Gelles is an American epidemiologist. She works for the United States Centers for Disease Control and Prevention and serves as a Commander in the United States Public Health Service Commissioned Corps.
Ruth Link-Gelles's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. (2015) (596)
- Serotype-Specific Changes in Invasive Pneumococcal Disease after Pneumococcal Conjugate Vaccine Introduction: A Pooled Analysis of Multiple Surveillance Sites (2013) (402)
- Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel Coronavirus Outbreak — United States, December 31, 2019–February 4, 2020 (2020) (337)
- Characteristics Associated with Hospitalization Among Patients with COVID-19 — Metropolitan Atlanta, Georgia, March–April 2020 (2020) (294)
- Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022 (2022) (267)
- Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States (2020) (245)
- Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022 (2022) (244)
- Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant — National Healthcare Safety Network, March 1–August 1, 2021 (2021) (232)
- First 12 patients with coronavirus disease 2019 (COVID-19) in the United States (2020) (139)
- Recommendations of the Advisory Committee on Immunization Practices for Use of a Hepatitis B Vaccine with a Novel Adjuvant (2018) (137)
- Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study. (2016) (134)
- Infection control assessment of ambulatory surgical centers. (2010) (117)
- National Update on Measles Cases and Outbreaks — United States, January 1–October 1, 2019 (2019) (115)
- Pneumococcal genome sequencing tracks a vaccine escape variant formed through a multi-fragment recombination event (2012) (109)
- Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network, 10 States, April 2021–January 2022 (2022) (97)
- Epidemiology of invasive pneumococcal disease among high-risk adults since the introduction of pneumococcal conjugate vaccine for children. (2013) (90)
- Early COVID-19 First-Dose Vaccination Coverage Among Residents and Staff Members of Skilled Nursing Facilities Participating in the Pharmacy Partnership for Long-Term Care Program — United States, December 2020–January 2021 (2021) (87)
- National update on measles cases and outbreaks — United States, January 1 – October 1, 2019 (2020) (80)
- Update: Recommendations of the Advisory Committee on Immunization Practices for Use of Hepatitis A Vaccine for Postexposure Prophylaxis and for Preexposure Prophylaxis for International Travel (2018) (61)
- Meningococcal Carriage Following a Vaccination Campaign With MenB-4C and MenB-FHbp in Response to a University Serogroup B Meningococcal Disease Outbreak—Oregon, 2015–2016 (2017) (61)
- Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance. (2022) (59)
- Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022 (2022) (57)
- Limited Secondary Transmission of SARS-CoV-2 in Child Care Programs — Rhode Island, June 1–July 31, 2020 (2020) (53)
- Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions. (2013) (46)
- Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 (2022) (45)
- Invasive Pneumococcal Disease Among Children With and Without Sickle Cell Disease in the United States, 1998 to 2009 (2013) (44)
- Use of surveillance data to estimate the effectiveness of the 7-valent conjugate pneumococcal vaccine in children less than 5 years of age over a 9 year period. (2012) (41)
- Public Health Response to a Case of Paralytic Poliomyelitis in an Unvaccinated Person and Detection of Poliovirus in Wastewater — New York, June–August 2022 (2022) (39)
- Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study (2022) (38)
- Geographic and temporal trends in antimicrobial nonsusceptibility in Streptococcus pneumoniae in the post-vaccine era in the United States. (2013) (38)
- Effect of the 2009 influenza A(H1N1) pandemic on invasive pneumococcal pneumonia. (2013) (36)
- Missed Opportunities: A National Survey of Obstetricians About Attitudes on Maternal and Infant Immunization (2012) (35)
- Forecasting invasive pneumococcal disease trends after the introduction of 13-valent pneumococcal conjugate vaccine in the United States, 2010-2020. (2013) (33)
- Community-Based Services to Improve Testing and Linkage to Care Among Non–U.S.-Born Persons with Chronic Hepatitis B Virus Infection — Three U.S. Programs, October 2014–September 2017 (2018) (31)
- Enhanced contact investigations for nine early travel-related cases of SARS-CoV-2 in the United States (2020) (29)
- Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months-5 Years - United States, June 2022. (2022) (28)
- Tuberculosis Immune Reconstitution Inflammatory Syndrome in Children Initiating Antiretroviral Therapy for HIV Infection: A Systematic Literature Review (2014) (26)
- Bias with respect to socioeconomic status: A closer look at zip code matching in a pneumococcal vaccine effectiveness study (2016) (26)
- Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022 (2022) (26)
- Effectiveness of Homologous and Heterologous Covid-19 Boosters against Omicron (2022) (25)
- Recombinant Zoster Vaccine (Shingrix) real-world effectiveness in the first two years post-licensure. (2021) (25)
- Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults — VISION Network, 10 States, December 2021–March 2022 (2022) (25)
- First-Dose COVID-19 Vaccination Coverage Among Skilled Nursing Facility Residents and Staff. (2021) (24)
- Use of hepatitis A vaccine for post-exposure prophylaxis in individuals over 40 years of age: A systematic review of published studies and recommendations for vaccine use. (2018) (24)
- Cost-Effectiveness of Using 2 vs 3 Primary Doses of 13-Valent Pneumococcal Conjugate Vaccine (2013) (24)
- Demographic and Social Factors Associated with COVID-19 Vaccination Initiation Among Adults Aged ≥65 Years — United States, December 14, 2020–April 10, 2021 (2021) (23)
- Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines — United States, October 2022 (2022) (22)
- Characteristics of Patients with Acute Flaccid Myelitis, United States, 2015–2018 (2020) (21)
- Prolonged and large outbreak of invasive group A Streptococcus disease within a nursing home: repeated intrafacility transmission of a single strain. (2019) (18)
- The Advisory Committee on Immunization Practices’ Recommendation for Use of Moderna COVID-19 Vaccine in Adults Aged ≥18 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-19 Vaccines — United States, February 2022 (2011) (17)
- Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant — United States, February 14–March 27, 2022 (2022) (17)
- Impact of 13-Valent Pneumococcal Conjugate Vaccine Used in Children on Invasive Pneumococcal Disease in Children and Adults in the United States : Analysis of Multisite , Population-based Surveillance (2016) (16)
- Paradoxical tuberculosis‐associated immune reconstitution inflammatory syndrome in children (2016) (15)
- Antibody Responses after Classroom Exposure to Teacher with Coronavirus Disease, March 2020 (2020) (14)
- Effectiveness of COVID-19 mRNA Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance — VISION Network, 10 States, December 2021—August 2022 (2022) (14)
- Streptococcus pneumoniae Serotype 15A in Psychiatric Unit, Rhode Island, USA, 2010–2011 (2012) (14)
- Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, December 2022–January 202 (2023) (11)
- Estimation of COVID-19 mRNA Vaccine Effectiveness Against Medically Attended COVID-19 in Pregnancy During Periods of Delta and Omicron Variant Predominance in the United States (2022) (11)
- Establishing a Timeline to Discontinue Routine Testing of Asymptomatic Pregnant Women for Zika Virus Infection — American Samoa, 2016–2017 (2017) (10)
- Streptococcus pneumoniae Serotype 15A in Psychiatric Unit (2012) (9)
- Association between COVID-19 mRNA vaccination and COVID-19 illness and severity during Omicron BA.4 and BA.5 sublineage periods (2022) (9)
- Strategies associated with COVID‐19 vaccine coverage among nursing home staff (2021) (9)
- Incidence of pharyngitis, sinusitis, acute otitis media, and outpatient antibiotic prescribing preventable by vaccination against group A Streptococcus in the United States. (2020) (9)
- COVID-19 Vaccine Uptake Among Residents and Staff Members of Assisted Living and Residential Care Communities—Pharmacy Partnership for Long-Term Care Program, December 2020–April 2021 (2021) (8)
- Characteristics and Risk Factors of Hospitalized and Nonhospitalized COVID-19 Patients, Atlanta, Georgia, USA, March–April 2020 (2021) (7)
- Characteristics of Intracranial Group A Streptococcal Infections in US Children, 1997-2014. (2018) (7)
- Investigating Health Disparities Associated With Multisystem Inflammatory Syndrome in Children After SARS-CoV-2 Infection (2022) (6)
- Public health response to a case of paralytic poliomyelitis in an unvaccinated person and detection of poliovirus in wastewater-New York, June-August 2022. (2022) (6)
- Ecological Analysis of the Decline in Incidence Rates of COVID-19 Among Nursing Home Residents Associated with Vaccination, United States, December 2020-January 2021 (2021) (6)
- Wastewater Testing and Detection of Poliovirus Type 2 Genetically Linked to Virus Isolated from a Paralytic Polio Case — New York, March 9–October 11, 2022 (2022) (6)
- Screening and linkage to care for hepatitis C among inpatients in Georgia's National Hospital Screening Program. (2020) (6)
- COVID-19 Vaccines: Safe and Effective in Children Ages 5-11 Years. (2022) (3)
- Outbreaks and infection control breaches in health care settings: Considerations for patient notification. (2020) (2)
- Long-term Protection Associated With COVID-19 Vaccination and Prior Infection. (2022) (2)
- Surveillance of COVID-19 Vaccination in Nursing Homes, United States, December 2020–July 2021 (2022) (2)
- Notes from the Field: Increase in Hepatitis A Virus Infections — Marshall Islands, 2016–2017 (2018) (2)
- Referrals of Infection Control Breaches to Public Health Authorities: Ambulatory Care Settings Experience, 2017. (2020) (1)
- Surveillance of COVID-19 vaccination in US nursing homes, December 2020-April 2021 (2021) (1)
- Regional Variation in Outpatient Antibiotic Prescribing for Acute Respiratory Tract Infections in a Commercially Insured Population, United States, 2017 (2023) (1)
- 23. Regional Variation in Outpatient Antibiotic Prescribing in a Commercially-insured Population, United States, 2017 (2020) (1)
- Generalisability of vaccine effectiveness estimates: an analysis of cases included in a postlicensure evaluation of 13-valent pneumococcal conjugate vaccine in the USA (2017) (1)
- Effectiveness of BNT162b2 COVID-19 Vaccination in Children and Adolescents. (2023) (0)
- Reduction in COVID-19-related mortality over time but disparities across population subgroups (2023) (0)
- Updated ACIP recommendations for use of hepatitis A vaccine and immune globulin for post-exposure prophylaxis and for international travelers (2017) (0)
- Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022 (2023) (0)
- Original Studies (2013) (0)
- Relative effectiveness of COVID-19 vaccination and booster dose combinations among 18.9 million vaccinated adults during the early SARS-CoV-2 Omicron period - United States, January 1, 2022-March 31, 2022. (2023) (0)
- Vaccinating to Prevent Antibiotic Use: Potential Impact of a Group A Streptococcus Vaccine on Acute Respiratory Infections (2020) (0)
- Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods (2023) (0)
- Preliminary Estimates of Effectiveness of Monovalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection Among Children Aged 3–5 Years — Increasing Community Access to Testing Program, United States, July 2022–February 2023 (2023) (0)
- Effectiveness of Booster Doses of Monovalent mRNA COVID-19 Vaccine Against Symptomatic SARS-CoV-2 Infection in Children, Adolescents, and Adults During Omicron Subvariant BA.2/BA.2.12.1 and BA.4/BA.5 Predominant Periods (2023) (0)
- Estimated COVID-19 vaccine effectiveness against seroconversion from SARS-CoV-2 Infection, March–October, 2021 (2023) (0)
- Antiviral Treatment among Hepatitis B Virus-Infected Pregnant Women—New York City and Michigan, 2013–2015 (2017) (0)
- Relationships between social vulnerability and COVID-19 vaccination coverage and vaccine effectiveness. (2023) (0)
- Impact of the COVID-19 Vaccination Program on case incidence, emergency department visits, and hospital admissions among children aged 5–17 Years during the Delta and Omicron Periods—United States, December 2020 to April 2022 (2022) (0)
- Breastfeeding duration and cytomegalovirus seroprevalence among U.S. children aged 1-5 years: The National Health and Nutrition Examination Surveys, 2011-2012 and 2017-2018. (2020) (0)
- Assessing COVID-19 vaccine effectiveness against Omicron subvariants: Report from a meeting of the World Health Organization (2023) (0)
- Are We Studying Who We Think We're Studying? Role of Socioeconomic Status in the Validity of Estimates of Pneumococcal Conjugate VaccineEffectiveness in the United States (2016) (0)
This paper list is powered by the following services:
Other Resources About Ruth Link-Gelles
What Schools Are Affiliated With Ruth Link-Gelles?
Ruth Link-Gelles is affiliated with the following schools:
